Genkyotex
Geneva
About Genkyotex
Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $87.1M
- Funding stage: M&A
- Last round: Post-IPO Equity (Feb 2020)
- Ticker: epa:GKTX
- Website: genkyotex.com
- Phone: 141228801013
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/genkyotex-2243720 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.